HC Wainwright Reaffirms Buy Rating for MediWound (NASDAQ:MDWD)

HC Wainwright reaffirmed their buy rating on shares of MediWound (NASDAQ:MDWD) in a report released on Thursday morning, Benzinga reports. The brokerage currently has a $28.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for MediWound’s FY2027 earnings at $1.28 EPS.

MDWD has been the topic of a number of other research reports. Maxim Group increased their price target on MediWound from $25.00 to $30.00 and gave the company a buy rating in a research note on Tuesday, July 16th. StockNews.com raised MediWound to a sell rating in a research note on Monday, August 5th.

MediWound Stock Up 6.1 %

Shares of MDWD opened at $19.27 on Thursday. The stock’s fifty day simple moving average is $17.45 and its 200-day simple moving average is $16.32. The firm has a market capitalization of $178.90 million, a PE ratio of -13.96 and a beta of 0.81. MediWound has a 12-month low of $7.10 and a 12-month high of $24.00.

MediWound (NASDAQ:MDWD) last released its earnings results on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The company had revenue of $4.96 million for the quarter, compared to the consensus estimate of $4.65 million. MediWound had a negative net margin of 64.24% and a negative return on equity of 21.67%. Analysts anticipate that MediWound will post -1.86 EPS for the current year.

Hedge Funds Weigh In On MediWound

Several institutional investors and hedge funds have recently modified their holdings of MDWD. Rosalind Advisors Inc. raised its holdings in shares of MediWound by 5.7% during the second quarter. Rosalind Advisors Inc. now owns 513,490 shares of the biopharmaceutical company’s stock worth $7,969,000 after acquiring an additional 27,500 shares during the period. Essex Investment Management Co. LLC lifted its holdings in shares of MediWound by 241.6% in the first quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock valued at $1,888,000 after purchasing an additional 93,705 shares in the last quarter. Yelin Lapidot Holdings Management Ltd. boosted its position in shares of MediWound by 45.7% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock worth $1,276,000 after buying an additional 39,348 shares during the period. Sargent Investment Group LLC grew its holdings in shares of MediWound by 7.0% during the fourth quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock worth $1,111,000 after buying an additional 7,125 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC lifted its stake in MediWound by 7.8% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock valued at $1,214,000 after acquiring an additional 6,200 shares in the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.